Literature DB >> 33284457

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.

Emek Kocatürk1, Andaç Salman2, Ivan Cherrez-Ojeda3, Paulo Ricardo Criado4, Jonny Peter5, Elif Comert-Ozer2, Mohamed Abuzakouk6, Rosana Câmara Agondi7, Mona Al-Ahmad8, Sabine Altrichter9, Rand Arnaout10, Luisa Karla Arruda11, Riccardo Asero12, Andrea Bauer13, Moshe Ben-Shoshan14, Jonathan A Bernstein15, Mojca Bizjak16, Isabelle Boccon-Gibod17, Hanna Bonnekoh18, Laurence Bouillet17, Zenon Brzoza19, Paula Busse20, Regis A Campos21, Emily Carne22, Niall Conlon23, Roberta F Criado24, Eduardo M de Souza Lima25, Semra Demir26, Joachim Dissemond27, Sibel Doğan Günaydın28, Irina Dorofeeva29, Luis Felipe Ensina30, Ragıp Ertaş31, Silvia Mariel Ferrucci32, Ignasi Figueras-Nart33, Daria Fomina34, Sylvie M Franken35, Atsushi Fukunaga36, Ana M Giménez-Arnau37, Kiran Godse38, Margarida Gonçalo39, Maia Gotua40, Clive Grattan41, Carole Guillet42, Naoko Inomata43, Thilo Jakob44, Gul Karakaya45, Alicja Kasperska-Zając46, Constance H Katelaris47, Mitja Košnik16, Dorota Krasowska48, Kanokvalai Kulthanan49, M Sendhil Kumaran50, Claudia Lang42, José Ignacio Larco-Sousa51, Elisavet Lazaridou52, Tabi Anika Leslie53, Undine Lippert54, Oscar Calderón Llosa55, Michael Makris56, Alexander Marsland57, Iris V Medina58, Raisa Meshkova59, Esther Bastos Palitot60, Claudio A S Parisi61, Julia Pickert62, German D Ramon63, Mónica Rodríguez-Gonzalez64, Nelson Rosario65, Michael Rudenko66, Krzysztof Rutkowski67, Jorge Sánchez68, Sibylle Schliemann69, Bulent Enis Sekerel70, Faradiba S Serpa71, Esther Serra-Baldrich72, Zhiqiang Song73, Angèle Soria74, Maria Staevska75, Petra Staubach76, Anna Tagka77, Shunsuke Takahagi78, Simon Francis Thomsen79, Regina Treudler80, Zahava Vadasz81, Solange Oliveira Rodrigues Valle82, Martijn B A Van Doorn83, Christian Vestergaard84, Nicola Wagner85, Dahu Wang86, Liangchun Wang87, Bettina Wedi88, Paraskevi Xepapadaki89, Esra Yücel90, Anna Zalewska-Janowska91, Zuotao Zhao92, Torsten Zuberbier93, Marcus Maurer94.   

Abstract

INTRODUCTION: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. AIM: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19.
MATERIALS AND METHODS: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.
RESULTS: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19.
CONCLUSIONS: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatment

Year:  2020        PMID: 33284457     DOI: 10.1111/all.14687

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  16 in total

1.  Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.

Authors:  Eli Magen; Avi Yakov; Ilan Green; Ariel Israel; Shlomo Vinker; Eugene Merzon
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

Review 2.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

3.  Chronic Urticaria: The Need for Improved Definition.

Authors:  R Maximiliano Gómez; Jonathan A Bernstein; Ignacio Ansotegui; Marcus Maurer
Journal:  Front Allergy       Date:  2022-06-09

4.  The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.

Authors:  Emel Atayik; Gokhan Aytekin
Journal:  Rev Fr Allergol (2009)       Date:  2022-06-13

5.  Recent advances and developments in COVID-19 in the context of allergic diseases.

Authors:  Mei Ding; Xiang Dong; Yuan-Li Sun; Milena Sokolowska; Mübeccel Akdis; Willem van de Veen; Ahmet Kursat Azkur; Dilek Azkur; Cezmi A Akdis; Ya-Dong Gao
Journal:  Clin Transl Allergy       Date:  2021-09       Impact factor: 5.657

6.  Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg?

Authors:  P R Criado; R F J Criado; R Gianotti; B A Z Abdalla; T P H Pincelli; A O Michalany; N S Michalany
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-09       Impact factor: 9.228

Review 7.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

8.  The COVID-19 Pandemic Affects Male Patients With Chronic Spontaneous Urticaria More Than Female Patients.

Authors:  Huzeyfe Kulu; Mustafa Atasoy; Kemal Özyurt; Marcus Maurer; Atıl Avcı; Muhammet Reşat Akkuş; Ragıp Ertaş
Journal:  Front Immunol       Date:  2021-10-11       Impact factor: 7.561

9.  Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.

Authors:  Maria Passante; Maddalena Napolitano; Stefano Dastoli; Luigi Bennardo; Gabriella Fabbrocini; Steven Paul Nisticò; Cataldo Patruno
Journal:  Dermatol Ther       Date:  2021-08-31       Impact factor: 3.858

Review 10.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Authors:  Marcus Maurer; Markus Magerl
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.